Skip to main content
. 2021 Nov 30;11:23163. doi: 10.1038/s41598-021-02667-4

Figure 4.

Figure 4

The ROC analysis of the ΔAEF, rAEF, ΔHAP, and the corresponding percentiles, PVPvariance, AEFkurtosisfor IMCC and HCC. ΔAEF Difference in arterial enhancement fraction (AEFtumor−AEFliver), rAEF Relative arterial enhancement fraction (ΔAEF/AEFliver), ΔHAP Difference in hepatic arterial perfusion (HAPtumor−HAPliver), PVPvariance The variance of the portal vein perfusion, AEFkurtosis The kurtosis value of the arterial enhancement fraction, ROC Receiver operating characteristic, IMCC Intrahepatic mass-forming cholangiocarcinoma, HCC Hepatocellular carcinoma.